MetaCap

Janux Therapeutics (JANX) vs Nuvectis Pharma (NVCT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Nuvectis Pharma (NVCT) has outperformed Janux Therapeutics (JANX) over the past year, gaining 218.9% versus a loss of 65.0%. Nuvectis Pharma is the larger company by market cap ($666.8 million vs $616.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

JANX-65.00%NVCT+218.91%
+391%+152%-87%
Nov 21, 20251 yearNov 20, 2026
JANX-34.20%NVCT+496.62%
+776%+338%-101%
Jan 31, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

JANX versus NVCT key metrics
MetricJANXNVCT
Share price$10.08$19.39
Market cap$616.73M$666.80M
1-day change-2.04%-2.27%
YTD return-26.96%+156.82%
1-year return-65.00%+218.91%
5-year return-42.92%—
EPS (TTM)$-1.59$-2.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$10.00M—
Revenue growth (YoY)-5.55%—
Net income (latest FY)$-113.63M$-26.44M
Operating margin-1576.67%—
Net margin-1136.25%—
52-week high$35.34$29.28
52-week low$10.05$5.77
Distance from 52-week high-71.48%-33.77%
Analyst consensusstrong_buynone
Avg. price target upside+228.77%+82.57%
Average volume961.56K206.37K
Shares outstanding61.18M34.39M
Employees11419
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NVCT has outperformed JANX by 283.9 percentage points over the past year.

About Janux Therapeutics

JANX stock →

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 114 employees

About Nuvectis Pharma

NVCT stock →

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

JANX vs NVCT FAQ

Which is bigger, Janux Therapeutics or Nuvectis Pharma?

Nuvectis Pharma (NVCT) is larger, with a market capitalization of $666.80M compared with $616.73M for Janux Therapeutics (JANX).

Which stock has performed better over the past year, JANX or NVCT?

NVCT returned +218.91% over the past 12 months, compared with -65.00% for JANX (price return, excluding dividends). Past performance does not predict future results.

Are Janux Therapeutics and Nuvectis Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons